

DAFTAR PUSTAKA

- Abbas, Abul K, Lichtman, Andrew H. and Pillai, S. (2016). *Basic Immunology: Functions and Disorders of the Immune System. American Journal of Epidemiology* (Vol. 155). <https://doi.org/10.1093/aje/155.2.185-a>
- Abbas, A. K., Lichtman, A., & Pillai, S. (2017). *Cellular and Molecular Immunology* (9th ed.). Philadelphia: Elsevier Inc.
- Al-Saleh, K., El-Aziz, N., Ali, A., Abozeed, W., El-Warith, A., Ibraheem, A., ... Nabholtz, J. (2017). Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. *Oncology Letters*, 337–344. <https://doi.org/10.3892/ol.2017.6144>
- Ali, H. R., Provenzano, E., Dawson, S., Blows, F. M., Liu, B., Shah, M., ... Caldas, C. (2014). Association between CD8 + T-cell infiltration and breast cancer survival in 12 439 patients, (June), 1536–1543. <https://doi.org/10.1093/annonc/mdu191>
- American cancer society. (2017). *Breast Cancer Facts and Figures 2017-2018*. Atlanta: American Cancer Society, Inc.
- Bjelobrk IK, Kapicl, TI., Jovanovic D., Trifunović J., Radic J., Vidovic, V., Vranjkovic B., Djan I., Popovic L. (2017). Clinical Relevance of Determination of Tumour Infiltrating Lymphocytes in Breast Carcinoma. *West Indian Medical Journal*. <https://doi.org/10.7727/wimj.2017.044>
- Bohling SD and Allison KH. (2008). Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. *Mod Pathol*, 21, 1527–1532. <https://doi.org/10.1038/modpathol.2008.160>
- Cimino-Mathews, A., Foote, JB., Emens, LA. (2015). Immune Targeting in Breast Cancer. *Oncology Journal, Breast Cancer*. <https://www.cancernetwork.com//oncology-journal/immune-targeting-breast-cancer>
- Damjanov, I. (2013). *Cancer Grading Manual*. (F. Damjanov, Ivan; Fan, Ed.) (2nd ed.). Springer. <https://doi.org/10.1007/978-3-642-34516-6>
- Denkert, C., Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, BI., Weber, KE., ... Loibl, S. (2018). Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol*, 19: 40–50. [http://dx.doi.org/10.1016/S1470-2045\(17\)30904-X](http://dx.doi.org/10.1016/S1470-2045(17)30904-X)
- Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. *Nature Immunology*, 3(11), 991–998. <https://doi.org/10.1038/ni1102-991>
- Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The Three Es of Cancer Immunoediting. *Annual Review of Immunology*, 22(1), 329–360. <https://doi.org/10.1146/annurev.immunol.22.012703.104803>

- Dushyanthen, S., Beavis, P. A., Savas, P., Teo, Z. L., Zhou, C., Mansour, M., ... Loi, S. (2015). Relevance of tumor-infiltrating lymphocytes in breast cancer. *BMC Medicine*, 13(1), 202. <https://doi.org/10.1186/s12916-015-0431-3>
- Ebili, HO., Oluwasola, AO., Olopade, OI. (2014). Molecular Subtypes of Breast Cancer. <https://www.researchgate.net/publication/285883478>
- Elston CW1, E. I. (2013). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Journal of Chemical Information and Modeling*, 53(9), 1689–1699. <https://doi.org/10.1017/CBO9781107415324.004>
- Fragomeni, SM., Sciallis, A., Jeruss, JS. (2018). Molecular subtypes and local-regional control of breast cancer. *Surg Oncol Clin N Am*, 95–120. <http://dx.doi.org/10.1016/j.soc.2017.08.005>
- Fukui R., Fujimoto Y., Watanabe T., Inoue N., Bun A., et al. (2020). Association Between FOXP3/CD8 Lymphocyte Ratios and Tumor Infiltrating Lymphocyte Levels in Different Breast Cancer Subtypes. *Anticancer Res*, 40(4), 2141-2150. <https://doi.org/10.21873/anticancer.14173>.
- GLOBOCAN 2018: Estimated cancer incidence, mortality and prevalence worldwide in 2018. (2018). Retrieved May, 2019, from <https://globocan.iarc.fr/factsheet.asp>
- Gobert, M., Treilleux, I., Bendriss-Vermare, N., et al. (2009). Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome. *Cancer Res*, 009; 69 : 2000-2009. <https://doi.org/10.1158/0008-5472.CAN-08-2360>
- Gooden, M. J. M., Bock, G. H. De, Leffers, N., Daemen, T., & Nijman, H. W. (2011). The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. *British Journal of Cancer*, 105(1), 93–103. <https://doi.org/10.1038/bjc.2011.189>
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. *Cell*, 144(5), 646–674. <https://doi.org/10.1016/j.cell.2011.02.013>
- Hinz S, Pagerols-Raluy L, Oberg HH., et al. (2007). Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. *Cancer Res*. 67, 8344–8350. <https://doi.org/10.1158/0008-5472.CAN-06-3304>.
- Hoda, S., Brogi, E., Koerner, F., & Rosen, P. (2015). *Rosen's Breast Pathology* (4th ed.). Philadelphia: Lippincott Williams & Wilkins.
- Jakubowska, K., Kisielewski, W., Kańczuga-Koda, L., Koda, M., & Famulski, W. (2017). Stromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma. *Oncology Letters*, 14(6), 6421–6432. <https://doi.org/10.3892/ol.2017.7013>
- Jung, Y.Y., Hyun C.L., Jin M.S., Park, I. A., Chung, Y.R., Shim, B., Lee, K.H., Ryu, H.S. (2016). *J Breast Cancer*, 19(3), 261-267

<http://dx.doi.org/10.4048/jbc.2016.19.3.261>

- Khedr R, Ghannam A, Ali M, El-Deen A. (2016). The Prognostic Role of Tumor-Infiltrating Lymphocytes CD8 and Foxp3 and their Impact on Recurrence in Breast Cancer Patients. *J Cancer Sci Ther*, 8(7), 206-212. DOI: 10.4172/1948-5956.1000414
- Kim, S., Lee, A., Lim, W., Park, S., Cho, MS., Koo, H., Moon, Bl., Suung, SH. (2014). Zonal Differencee Prognostic Significancee of Foxp3 Regulatory T Cell Infiltration in Breast Cancer. *Journal of Breast Cancer*, 17(1), 8-17. <https://doi.org/10.4048/jbc.2014.17.1.8>.
- Kumar, Vinay; Abbas, A. A. J. (Ed.). (2015). *Robbins & Cotran Pathologic Basis of Disease* (9th ed.). Philadelphia: Elsevier Saunders.
- Lakhani, S. (2012). *WHO Classification of Tumours of The Breast*. (M. Lakhani, Sunil; Ellis, Ian; Schnitt, Stuart; Tan, Puay; van de Vijver, Ed.) (4th ed., Vol. 92). Lyon, France: International Agency for Research on Cancer. <https://doi.org/10.1017/CBO9781107415324.004>
- Liu, S., Foulkes, WD., Leung, Gao, D., Lau, S., Kos, Z., Nielson, TO. (2014). Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. *Breast Cancer Research*, 16:432. <http://breast-cancer-research.com/content/16/5/432>
- Loi, S., Drubay, D., Adams, S., Pruneri, G., Francis, PA., Lacroix-Triki, M., ... Michiels, S. (2019). Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. *J Clin Oncol*, 37 : 559-569. <https://doi.org/10.1200/JCO.18.01010>.
- Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., ... Green, A. R. (2011). Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. *Journal of Clinical Oncology*, 29(15), 1949–1955. <https://doi.org/10.1200/JCO.2010.30.5037>
- Martin, F., Ladoire, S., Mignot, G., Apetoh, L., and Ghiringhelli F. (2010). Human FOXP3 and cancer. *Oncogene*. 29, 4121–4129.
- Mathai, AM., Kapadia, MJ., Alexander, J., Kernochan, LE., Swanson, PE. (2012). Role of Foxp3-positive Tumor-infiltrating Lymphocytes in the Histologic Features and Clinical Outcomes of Hepatocellular Carcinoma. *The American Journal of Surgical Pathology*, 36(7), 980-986. <https://doi.org/10.1097/PAS.0b013e31824e9b7c>
- Nishikawa, H., & Sakaguchi, S. (2010). Regulatory T cells in tumor immunity, 767, 759–767. <https://doi.org/10.1002/ijc.25429>
- Ohara, M., Yamaguchi, Y., Matsuura, K., Murakami, S., Arihiro, K., and Okada, M. (2009). Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. *Cancer Immunol Immunother*, 58(3), 441–447. <https://doi.org/10.1007/s00262-008-0570-x>
- Papadimitriou, M., Kaptanis, S., Polymeropoulos, E., Mitsopoulos, G.,

- Stogiannis, D., Caroni, C., ... Karakitsos, P. (2015). Nuclear Grade Plus Proliferation Grading System for Invasive Ductal Carcinoma of the Breast Validation in a Tertiary Referral Hospital Cohort. *Am J Clin Pathol*, 144: 837-843. <https://doi.org/10.1309/AJCPVH6FED2ZATUP>
- Pitt, J. M., Marabelle, A., Eggermont, A., Soria, J. C., Kroemer, G., & Zitvogel, L. (2016). Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy. *Annals of Oncology*, 27(8), 1482–1492. <https://doi.org/10.1093/annonc/mdw168>
- Pujani, M., Jain, H., Chauhan, V., Agarwal, C., Singh, K., Singh, M. (2020). Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage. *Breast Disease*, 39(2), 61-69. <https://doi.org/10.3233/BD-200442>
- Rosai, J. (2011). *ROSAI & ACKERMAN'S Surgical Pathology*. (J. Rosai, Ed.) (10th ed.). London: Elsevier.
- Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., ... Loi, S. (2015). The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILS Working Group 2014. *Annals of Oncology*, 26(2), 259–271. <https://doi.org/10.1093/annonc/mdu450>
- Shou, J., Zhang, Z., Lai, Y., Chen, Z., Huang, J. (2016). Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis. *BMC Cancer*, 16:687. <https://doi.org/10.1186/s12885-016-2732-0>
- Simpson, P. T., Reis-Filho, J. S., Gale, T., & Lakhani, S. R. (2005). Molecular evolution of breast cancer. *The Journal of Pathology*, 205(2), 248–254. <https://doi.org/10.1002/path.1691>
- Stickeler, E. (2011). Prognostic and predictive markers for treatment decisions in early breast cancer. *Breast Care*, 6(3), 193–198. <https://doi.org/10.1159/000329471>
- Suyatno, Emir, TP. (2009). *Bedah Onkologi Diagnostik dan Terapi*. Jakarta: Sagung Seto.
- Takenaka, M., Seki, N., Toh, U., Hattori, S., Kawahara, A., Yamaguchi, T., Koura, K., Takahashi, R. (2013). FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. *Molecular and Clinical Oncology*, 1, 625-632. <https://doi.org/10.3892/mco.2013.107>
- Taneja, P., Maglic, D., Kai, F., Zhu, S., Kendig, R. D., Fry, E. A., & Inoue, K. (2010). Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. *Clin Med Insights Oncol*, 4, 15–34.
- Torre, LA., Bray, F., Siegel, RL., Ferlay, J., Lortet-Tieulent, J., Jemal, A. (2015). Global Cancer Statistics. *CA Cancer J Clin* : 65(2), 87–108. <https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21262>
- vanLint, S., vanNuffel, AMT., Wilgenhof, S., Benteyn, D., Pen, J., Escors3, D., ... Breckpot, K. (2013). Priming of Cytotoxic T Lymphocyte

- Responses by Dendritic Cells: Induction of Potent Anti-tumor Immune Responses. *Horizons in Cancer Research*.
<https://www.researchgate.net/publication/277141183>
- West, N. R., Milne, K., Truong, P. T., Macpherson, N., Nelson, B. H., & Watson, P. H. (2011). Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. *Breast Cancer Research*, 13(6), R126.
<https://doi.org/10.1186/bcr3072>
- Yamaguchi, R., Tanaka, M., Yano, A., Tse, G. M., Yamaguchi, M., Koura, K., ... Yano, H. (2012). Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. *Human Pathology*, 43(10), 1688–1694.
<https://doi.org/10.1016/j.humpath.2011.12.013>
- Young, B., Lowe, J. S., Stevens, A., & Heath, J. W. (2006). *Wheater's Functional Histology: A Text and Colour Atlas*. Churchill Livingstone.
<https://doi.org/10.7861/clinmedicine.14-4-453>
- Zaha, DC. (2014). Significance of Immunohistochemistry in Breast Cancer. *World J Clin Oncol*, 5(3): 382-92. <https://doi.org/10.5306/wjco.v5.i3.382>
- Zgura, A., Galesa, L., Bratilaa, E., Anghel, R. (2018). Relationship between Tumor Infiltrating Lymphocytes and Progression in Breast Cancer. *MAEDICA – a Journal of Clinical Medicine*.
<https://doi.org/10.26574/maedica.2018.13.4.317>